You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
The diagnostic is composed of Agilent's Bravo automation workstation and Mammoth's DETECTR BOOST SARS-CoV-2 assay.
The contract was awarded under DARPA's Detect It with Gene Editing Technologies program, which aims to create a device to detect at least 10 pathogens.
The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated.
The two new tests, which have the capability to quantify a patient's viral load, have been designed without external RNA extraction or amplification steps.
The funding will help the company further develop its INSPECTR molecular diagnostic platform into a test that can be used in various settings.